Filed pursuant to Rule 424(b)(3)
File No. 333-283109
PROSPECTUS SUPPLEMENT
(To Prospectus dated November 8, 2024, as supplemented
by the Prospectus Supplement dated November 12, 2024 and
by the Prospectus Supplement dated January 28, 2025) |
|
February 11, 2025 |

Oxford Lane Capital Corp.
$2,000,000,000
Common Stock
This prospectus supplement
contains information which amends, supplements and modifies certain information contained in the prospectus dated November 8, 2024 (the
“Base Prospectus”) as supplemented by the prospectus supplement dated November 12, 2024 (the “November 2024 Prospectus
Supplement”) and the prospectus supplement dated January 28, 2025 (the “January 2025 Prospectus Supplement” and, together
with the November 2024 Prospectus Supplement, this prospectus supplement and the Base Prospectus, the “Prospectus”), which
relate to the sale of shares of common stock of Oxford Lane Capital Corp. (the “Company”) in an “at-the-market”
offering pursuant to an Amended and Restated Equity Distribution Agreement dated September 9, 2022, as amended pursuant to that certain
Amendment No. 1, dated as of November 15, 2023, that certain Amendment No. 2, dated as of July 29, 2024, and that certain Amendment No.
3, dated as of November 12, 2024 (collectively, the “Amended Equity Distribution Agreement”), with Lucid Capital Markets,
LLC and Ladenburg Thalmann & Co. Inc. (the “Distribution Agents”). The Company’s investment adviser, Oxford Lane
Management, LLC, has agreed to pay to the Distribution Agents, if necessary, a supplemental payment per share that will reflect the difference
between the public offering price per share and the net proceeds per share received by the Company in this offering such that the net
proceeds per share received by the Company (before expenses) are not below the Company’s then current net asset value per share.
You should carefully read
the entire Prospectus before investing in our common stock. You should also review the information set forth under the “Risk
Factors” section beginning on page 15 of the Base Prospectus and in our subsequent filings with the Securities and Exchange Commission
that are incorporated by reference into the Prospectus, before investing.
The terms “Oxford Lane,”
the “Company,” “we,” “us” and “our” generally refer to Oxford Lane Capital Corp.
PRIOR SALES PURSUANT TO THE “AT THE MARKET”
OFFERING
From November 12, 2024
to February 7, 2025, we sold a total of 69,685,583 shares of common stock pursuant to the “at-the-market” offering. The
total amount of capital raised as a result of these sales of common stock was approximately $352.6 million and net proceeds were
approximately $350.7 million, after deducting the sales agents’ commissions and offering expenses.
JANUARY
2025 FINANCIAL UPDATE
On
February 10, 2025, we announced the following net asset value (“NAV”) estimate as of January 31, 2025.
| ● | Management’s unaudited estimate of the
range of the NAV per share of our common stock as of January 31, 2025, is between $4.78 and $4.88. This estimate is not a comprehensive
statement of our financial condition or results for the month ended January 31, 2025. This estimate did not undergo the Company’s
typical quarter-end financial closing procedures and was not approved by the Company’s board of directors. We advise you that our
NAV per share for the quarter ending March 31, 2025 may differ materially from this estimate, which is given only as of January 31, 2025.
|
| ● | As of January 31, 2025, the Company had approximately
406.8 million shares of common stock issued and outstanding. |
The fair value of the Company’s portfolio investments may be
materially impacted after January 31, 2025, by circumstances and events that are not yet known. To the extent the Company’s portfolio
investments are impacted by market volatility in the U.S. or worldwide, the Company may experience a material impact on its future net
investment income, the fair value of its portfolio investments, its financial condition and the financial condition of its portfolio investments.
Investing in our securities involves a number of significant risks. For a discussion of the additional risks applicable to an investment
in our securities, please refer to the section titled “Risk Factors” in our prospectus and the section titled “Principal
Risks” in our most recent annual report or semi-annual report, as applicable.
The
preliminary financial data included in this prospectus supplement has been prepared by, and is the responsibility of, Oxford Lane
Capital Corp.’s management. PricewaterhouseCoopers LLP has not audited, reviewed, compiled, or applied agreed-upon procedures
with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other
form of assurance with respect thereto. The PricewaterhouseCoopers LLP report incorporated by reference relates to the Company’s
previously issued financial statements. It does not extend to the preliminary financial data and should not be read to do so.
424B3
0001495222
false
0001495222
2025-02-11
2025-02-11
0001495222
2025-01-31
2025-01-31
xbrli:shares
iso4217:USD
xbrli:shares